Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006-2010.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Hepatology

• Publication date

  2015-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jhep.2015.04.021PMID 25937437PMCID PMC5675515
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Predictors of poor mental and physical health status among patients with chronic hepatitis C infection: The Chronic Hepatitis Cohort Study (CHeCS)

  2015cited by this paper
• Chronic Hepatitis C Virus Infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010

  2014cited by this paper
• P1034 ESTIMATED PREVALENCE OF HCV CIRRHOSIS IN THE CHRONIC HEPATITIS COHORT STUDY (CHECS)

  2014cited by this paper
• EASL recommendations on treatment of hepatitis C 2014.

  2014cited by this paper
• Risk of Pancreatic Cancer in Relation to ABO Blood Group and Hepatitis C Virus Infection in Korea: A Case-Control Study

  2013cited by this paper
• Baseline characteristics and mortality among people in care for chronic viral hepatitis: the chronic hepatitis cohort study.

  2013cited by this paper
• Health behaviors of adults: United States, 2008-2010.

  2013cited by this paper
• Hepatitis C in the United States.

  2013cited by this paper
• Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study.

  2012cited by this paper
• The importance of blood-borne viruses in elevated cancer risk among opioid-dependent people: a population-based cohort study

  2012cited by this paper
• Positive Association Between Hepatitis C Infection and Oral Cavity Cancer: A Nationwide Population-Based Cohort Study in Taiwan

  2012cited by this paper
• The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007

  2012cited by this paper
• Association between chronic viral hepatitis infection and breast cancer risk: a nationwide population-based case-control study

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• Risk for Renal Cell Carcinoma in Chronic Hepatitis C Infection

  2010cited by this paper
• Hepatitis C virus infection and antiviral treatment in marginal zone lymphomas.

  2010cited by this paper
• Hepatitis C virus infection and risk of cancer: a population-based cohort study

  2010cited by this paper
• Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

  2009cited by this paper
• Hepatitis C virus-related kidney disease: an overview.

  2008cited by this paper
• Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003.

  2008cited by this paper
• Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium.

  2008cited by this paper
• Hepatitis C virus and risk of non‐Hodgkin lymphoma in British Columbia, Canada

  2008cited by this paper
• Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus.

  2007cited by this paper
• Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH.

  2006cited by this paper
• The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.

  2006cited by this paper
• Hepatitis C virus RNA and core protein in kidney glomerular and tubular structures isolated with laser capture microdissection

  2005cited by this paper
• Non‐Hodgkin's lymphoma and other nonhepatic malignancies in Swedish patients with hepatitis C virus infection

  2005cited by this paper
• Global epidemiology of hepatitis C virus infection.

  2005cited by this paper
• Role of hepatitis C virus infection in malignant lymphoma in Spain

  2004cited by this paper
• Prevalence and Epidemiology of Hepatitis C Virus in Patients with Squamous Cell Carcinoma of the Head and Neck

  2004cited by this paper
• Risk of thyroid cancer and high prevalence of hepatitis C virus.

  2003cited by this paper
• Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection.

  2002cited by this paper
• ERBB‐2 overexpression and cyclooxygenase‐2 up‐regulation in human cholangiocarcinoma and risk conditions

  2002cited by this paper
• Extrahepatic manifestations of hepatitis C among United States male veterans

  2002cited by this paper
• Oral lichen planus: a potentially premalignant lesion.

  2000cited by this paper
• Detection of hepatitis C virus RNA in oral lichen planus and oral cancer tissues.

  2000cited by this paper
• Hepatitis C Virus Infection in Patients with B-Cell Non-Hodgkin Lymphoma

  1997cited by this paper
• Hepatitis C: A Multifaceted Disease: Review of Extrahepatic Manifestations

  1995cited by this paper
• High prevalence of hepatitis C virus antibody and RNA in patients with oral cancer.

  1995cited by this paper

• Long‐Term Mortality Following Hepatitis C Cure in a Real‐World Multinational Cohort

  2026cites this paper
• Death From Infection Among Patients Living With Cancer.

  2025cites this paper
• Pancreatic Ductal Adenocarcinoma After Hepatitis C Infection

  2025cites this paper
• Antiviral treatment Reduces Risk of Development of Lung Cancer and non-Hodgkin Lymphoma in Patients with Chronic Hepatitis C.

  2025cites this paper
• Contemporary trends in extrahepatic mortality of chronic liver disease in the United States from 2014 to 2023

  2025cites this paper
• Identifying environmental factors and biological metrics associated with cancer prevalence and mortality: An environment-wide association study.

  2025cites this paper
• Two-way increased-risk associations between hepatobiliary cancers and other malignancies: a population-based study

  2025cites this paper
• Metallothioneins in the Pathogenesis of Liver Diseases: A Review

  2025influential citation
• A comprehensive review of phytoconstituents in liver cancer prevention and treatment: targeting insights into molecular signaling pathways

  2024cites this paper
• No association between hepatitis C virus infection and risk of colorectal cancer: a systematic review and meta-analysis of cohort studies

  2024cites this paper
• Unraveling the connection: Hepatitis C Virus (HCV) and Acute Myelogenous Leukemia (AML) in the absence of antiviral therapy

  2024cites this paper
• The HCV-Melanoma Paradox: First Multi-Cohort and Molecular Net-Work Analysis Reveals Lower Incidence but Worse Outcomes—Integrating Clinical, Real-World, and In Silico Data

  2024cites this paper
• Multi-Omics Analysis Reveals the IFI6 Gene as a Prognostic Indicator and Therapeutic Target in Esophageal Cancer

  2024cites this paper
• Neuropsychiatric and Laboratory Outcomes of Hepatitis C Treatment in an Early-Treated HIV Cohort in Thailand

  2024cites this paper
• Hygienic requirements regarding to population safety for cancirogenic factors of biological nature (a review)

  2024cites this paper
• All-cause and cause-specific mortality risk among men and women with hepatitis C virus infection

  2024cites this paper
• Implementation of Universal Hepatitis C Virus Screening in a Tertiary Cancer Center.

  2024cites this paper
• Accelerated Phenotypic Aging Associated with Hepatitis C Infection: Results from the U.S. National Health and Nutrition Examination Surveys 2015-2018.

  2024cites this paper
• Different Metabolic Associations of Hepatitis C With Colon and Rectal Cancers: A 9-Year Nationwide Population-Based Cohort Study.

  2024cites this paper
• When and in Whom to Initiate HCV Therapy

  2023cites this paper
• Hepatitis C accelerates extrahepatic cholangiocarcinoma risk: a joint study of hospital-based cases and nationwide population-based cohorts in a viral hepatitis-endemic area.

  2023cites this paper
• Pan-cancer analyses reveal the stratification of patient prognosis by viral composition in tumor tissues

  2023cites this paper
• When and in Whom to Initiate HCV Therapy

  2023cites this paper
• Neobavaisoflavone induces pyroptosis of liver cancer cells via Tom20 sensing the activated ROS signal.

  2023cites this paper
• Improving the prognosis of pancreatic cancer: insights from epidemiology, genomic alterations, and therapeutic challenges

  2023cites this paper
• Survival analysis over a 20-year period of a Brazilian cohort of blood donors coinfected HIV-HCV

  2023cites this paper
• When and in Whom to Initiate HCV Therapy

  2023cites this paper
• Association between hepatitis B or hepatitis C virus infection and risk of pancreatic cancer: a systematic review and meta-analysis of cohort studies

  2023cites this paper
• Relationship between hepatitis C virus infection and extrahepatic malignancies

  2023cites this paper
• Immunotherapy in cancer patients with chronic hepatitis C viral infection

  2023cites this paper
• When and in Whom to Initiate HCV Therapy

  2023cites this paper
• Effectiveness of sofosbuvir/ledipasvir in hepatitis C virus infection in children and adolescents with malignancy: tertiary center experience

  2022cites this paper
• Effectiveness of hepatitis C antiviral treatment and feasibility of hepatitis C elimination goal

  2022cites this paper
• Co-infections, comorbidities, and alcohol or other substances abuses in chronic hepatitis C-related hospitalisations in Spain

  2022cites this paper
• When and in Whom to Initiate HCV Therapy

  2022cites this paper
• Differential role of chronic liver diseases on the incidence of cancer: a longitudinal analysis among 248,224 outpatients in Germany

  2022influential citation
• When and in Whom to Initiate HCV Therapy

  2022cites this paper
• When and in Whom to Initiate HCV Therapy

  2022cites this paper
• Clinical, Biological, Immunological and Therapeutic Profile of Patients Co-Infected with HIV-HBV and/or HCV in Kinshasa, in the Democratic Republic of the Congo: Multicenter Cross-Sectional Study

  2022cites this paper
• Mac‐2‐binding protein glycan isomer predicts all malignancies after sustained virological response in chronic hepatitis C

  2022cites this paper
• The clinical impact of direct-acting antiviral treatment on patients affected by hepatitis C virus-related oral lichen planus: a cohort study

  2022cites this paper
• Mortality among Alaska Native Adults with Confirmed Hepatitis C Virus Infection Compared with the General Population in Alaska, 1995–2016

  2022cites this paper
• Prevalence and Spectrum of Second Primary Malignancies among People Living with HIV in the French Dat’AIDS Cohort

  2022cites this paper
• Aristolochic acid and the risk of cancers in patients with type 2 diabetes: Nationwide population-based cohort study.

  2022cites this paper
• Hepatitis C virus-associated B-cell lymphomas: The importance of the new direct antiviral agent therapy.

  2022cites this paper
• Association between breast cancer and hepatitis C: A joint study of hospitalized patients and nationwide cohorts.

  2022cites this paper
• Chronic hepatitis C infection is associated with higher incidence of extrahepatic cancers in a Canadian population based cohort

  2022cites this paper
• Impact of Interferon-Free Direct-Acting Antivirals on the Incidence of Extrahepatic Malignancies in Patients with Chronic Hepatitis C

  2022cites this paper
• HCV-related lymphoproliferative disorders in the direct-acting antivirals era: from mixed cryoglobulinemia to B-cell lymphoma.

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• Association between viral infection other than human papillomavirus and risk of esophageal carcinoma: a comprehensive meta-analysis of epidemiological studies

  2021cites this paper
• Screening and prevention of hepatitis C virus reactivation during chemotherapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• Hepatitis C coinfection and extrahepatic cancer incidence among people living with HIV

  2021cites this paper
• Accelerated cardiovascular risk after viral clearance in hepatitis C patients with the NAMPT-rs61330082 TT genotype: An 8-year prospective cohort study

  2021cites this paper
• Patients With Chronic Hepatitis C Virus Infection Are at an Increased Risk of Colorectal Cancer: A Nationwide Population-Based Case-Control Study in Taiwan

  2021cites this paper
• Hepatitis C as a Potential Risk Factor for Adverse Surgical Outcomes in Head and Neck Free Tissue Transfer Reconstruction

  2021cites this paper
• High Seroprevalence of Hepatitis C Virus Antibody in Breast Cancer Patients in Egypt

  2021cites this paper
• Treatment for liver cancer: From sorafenib to natural products.

  2021cites this paper
• Association Between Chronic Hepatitis C Virus Infection and Esophageal Cancer

  2021cites this paper
• Elevated risk of colorectal, liver, and pancreatic cancers among HCV, HBV and/or HIV (co)infected individuals in a population based cohort in Canada

  2021cites this paper
• Extrahepatic Manifestations of Hepatitis C Virus Infection

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• Association between Hepatitis C Virus Infection and Esophageal Cancer: An Asian Nationwide Population-Based Cohort Study

  2021cites this paper
• Review on Hepatitis C

  2021influential citation
• Polymorphism Rs34562254 In TNFRSF13B is Associated with HCV Infection Outcomes Among Chinese Han Population

  2021cites this paper
• The TNFRSF13B rs34562254 Polymorphism is Associated with Hepatitis C Infection Risk in the Han Chinese Population

  2021cites this paper
• Direct, indirect and total effect of HIV coinfection on the risk of non‐liver‐related cancer in hepatitis C virus‐infected patients treated by direct‐acting antivirals: a mediation analysis

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• Associations between hepatitis B virus exposure and the risk of extrahepatic digestive system cancers: A hospital‐based, case–control study (SIGES)

  2021cites this paper
• Association Between Proton Pump Inhibitor Use and Biliary Tract Cancer Risk: A Swedish Population‐Based Cohort Study

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• Risk of severe clinical events after sustained virological response following direct‐acting antiviral therapy in HIV and hepatitis C virus coinfected participants

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• Decreased Overall Survival in HIV-associated Non-small-cell Lung Cancer.

  2020cites this paper
• Factors and HCV treatment outcomes associated with smoking among people who inject drugs on opioid agonist treatment: secondary analysis of the PREVAIL randomized clinical trial

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• Will prior health insurance authorization for medications continue to hinder hepatitis C treatment delivery in the United States? Perspectives from hepatitis C treatment providers in a large urban healthcare system

  2020cites this paper
• Association of hepatitis C infection and risk of kidney cancer: A systematic review and meta‐analysis of observational studies

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper